Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004465 · ClinicalTrials.gov registry record · Phase 3
Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome
A Phase 3 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Terminated
- Registry status
- Phase 3
- Development phase
- 145
- Enrollment target
NCT00004465 is a Phase 3 study that was terminated before completion, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 145 participants.
The verdict
NCT00004465, a Phase 3 study, was terminated before completion, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 145 participants
- Enrollment target
Study Summary
OBJECTIVES: I. Determine the effect of SYNSORB Pk therapy on mortality and frequency of severe extrarenal complications observed in children with acute stage E. coli-associated hemolytic uremic syndrome. II. Determine the effect of SYNSORB Pk therapy on the need for the duration of dialysis in these patients. III. Determine the effect of SYNSORB Pk therapy on the recovery of renal function and resolution of urinary abnormalities in these patients.
Interventions
- DRUG Placebo
- DRUG SYNSORB Pk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 1997-07-27 |
| Est. Completion | 2001-04-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004465
The ClinicalTrials.gov registry entry for NCT00004465 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00004465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004465 about?
NCT00004465 is a clinical study titled "Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome". OBJECTIVES: I. Determine the effect of SYNSORB Pk therapy on mortality and frequency of severe extrarenal complications observed in children with acute stage E. coli-associated hemolytic uremic syndrome. II. Determine the effect of SYNSORB Pk therapy on the need for the duration of dialysis in thes...
What is the current status of trial NCT00004465?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 145 participants. The study started on 1997-07-27. Estimated completion is 2001-04-14.
What interventions are being tested in trial NCT00004465?
The interventions under investigation include: Placebo (DRUG), SYNSORB Pk (DRUG).
Who is sponsoring clinical trial NCT00004465?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.